ESMO 2022 Conference Coverage


 

ESMO 2022 on the Phase 3 HIMALAYA Study: Impact of Viral Aetiology of Tremelimumab + Durvalumab in Unresectable HCC

79 views
September 30, 2022
Comments 0
Login to view comments. Click here to Login